Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

Yu, HA; Cantero, F; Kim, B; Lee, M; Wu, E; Sternberg, DW; Janne, PA

ANNALS OF ONCOLOGY, 2022; 33 (7): S1092